- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.03. | H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy | 3 | Investing.com | ||
| 16.03. | Lyell Immunopharma: Citizens bestätigt "Market Outperform" nach Fortschritten in Studien | 1 | Investing.com Deutsch | ||
| 16.03. | Citizens reiterates Lyell Immunopharma stock rating on trial progress | 1 | Investing.com | ||
| 12.03. | Lyell Immunopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Lyell Immunopharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 09.03. | Lyell Immunopharma closes $50M equity tranche, names new CFO | 1 | Investing.com | ||
| 09.03. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer | 1 | GlobeNewswire (USA) | ||
| 09.03. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | Citizens initiates Lyell Immunopharma stock at outperform, $34 target | 1 | Investing.com | ||
| 12.02. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma | 1.043 | GlobeNewswire (Europe) | PiNACLE - H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell... ► Artikel lesen | |
| 22.12.25 | Lyell Immunopharma pops on recent ASH data, immunotherapy expansion | 4 | Seeking Alpha | ||
| 07.12.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 05.12.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Lyell Immunopharma reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.25 | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Lyell Immunopharma buys exclusive global rights to colorectal cancer drug | 1 | Seeking Alpha | ||
| 10.11.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer | 186 | GlobeNewswire (Europe) | LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal... ► Artikel lesen | |
| 10.11.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Lyell Immunopharma: Vielversprechende Daten zu dualer CAR-T-Zelltherapie bei Lymphomen | 1 | Investing.com Deutsch | ||
| 03.11.25 | Lyell Immunopharma, Inc: Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| EDITAS MEDICINE | 2,430 | -3,19 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| GALAPAGOS NV | 24,380 | +0,25 % | Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal | FOSTER CITY (dpa-AFX) - Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity... ► Artikel lesen | |
| IMMATICS | 8,970 | +0,90 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,300 | +1,56 % | H.C. Wainwright bestätigt Kaufempfehlung für Autolus und verweist auf B-ALL-Marktchancen | ||
| TANGO THERAPEUTICS | 19,960 | -3,50 % | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings | ||
| TSCAN THERAPEUTICS | 1,040 | -0,48 % | H.C. Wainwright bestätigt Kaufempfehlung für Tscan-Aktie mit Kursziel 7 US-Dollar | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen LYELL IMMUNOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -1,380 (-5,79 %) liegt der Kurs bei 22,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.